These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 28125373)

  • 1. Health Care Resource Utilization and Costs in Patients with Chronic Myeloid Leukemia with Better Adherence to Tyrosine Kinase Inhibitors and Increased Molecular Monitoring Frequency.
    Latremouille-Viau D; Guerin A; Gagnon-Sanschagrin P; Dea K; Cohen BG; Joseph GJ
    J Manag Care Spec Pharm; 2017 Feb; 23(2):214-224. PubMed ID: 28125373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between regular molecular monitoring and tyrosine kinase inhibitor therapy adherence in chronic myelogenous leukemia in the chronic phase.
    Guérin A; Chen L; Dea K; Wu EQ; Goldberg SL
    Curr Med Res Opin; 2014 Jul; 30(7):1345-52. PubMed ID: 24640967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-World Economic Outcomes During Time on Treatment Among Patients Who Initiated Sunitinib or Pazopanib as First Targeted Therapy for Advanced Renal Cell Carcinoma: A Retrospective Analysis of Medicare Claims Data.
    Vogelzang NJ; Pal SK; Ghate SR; Li N; Swallow E; Peeples M; Zichlin ML; Meiselbach MK; Perez JR; Agarwal N
    J Manag Care Spec Pharm; 2018 Jun; 24(6):525-533. PubMed ID: 29799328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tyrosine Kinase Inhibitors Initiation, Cost Sharing, and Health Care Utilization in Patients with Newly Diagnosed Chronic Myeloid Leukemia: A Retrospective Claims-Based Study.
    Phuar HL; Begley CE; Chan W; Krause TM
    J Manag Care Spec Pharm; 2019 Oct; 25(10):1140-1150. PubMed ID: 31556823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative evaluation of patients newly initiating first-generation versus second-generation tyrosine kinase inhibitors for chronic myeloid leukemia and medication adherence, health services utilization, and healthcare costs.
    Ward MA; Fang G; Richards KL; Walko CM; Earnshaw SR; Happe LE; Blalock SJ
    Curr Med Res Opin; 2015 Feb; 31(2):289-97. PubMed ID: 25420131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tyrosine Kinase Inhibitors and the Relationship With Adherence, Costs, and Health Care Utilization in Commercially Insured Patients With Newly Diagnosed Chronic Myeloid Leukemia: A Retrospective Claims-Based Study.
    Phuar HL; Begley CE; Chan W; Krause TM
    Am J Clin Oncol; 2020 Jul; 43(7):517-525. PubMed ID: 32304434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment patterns and healthcare costs among newly-diagnosed patients with chronic myeloid leukemia receiving dasatinib or nilotinib as first-line therapy in the United States.
    Latremouille-Viau D; Guerin A; Nitulescu R; Gagnon PS; Joseph GJ; Chen L
    J Med Econ; 2017 Jan; 20(1):63-71. PubMed ID: 27603674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia.
    Wu EQ; Guerin A; Yu AP; Bollu VK; Guo A; Griffin JD
    Curr Med Res Opin; 2010 Dec; 26(12):2861-9. PubMed ID: 21062136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health Care Resource Utilization and Costs Associated with Corticosteroid Use in Patients with Castration-Resistant Prostate Cancer: An Administrative Claims Analysis.
    Schultz NM; Penson DF; Wilson SD; Song Y; Yang H; Ramaswamy K; Lowentritt B
    J Manag Care Spec Pharm; 2019 Aug; 25(8):889-897. PubMed ID: 31172866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two-Way Clinical Messaging in a CML Specialty Pharmacy Service Model.
    Sawicki C; Friend KE; Patel R; Polinski JM; Singh S
    J Manag Care Spec Pharm; 2019 Nov; 25(11):1290-1296. PubMed ID: 31663460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Burden of Infections Among Chronic Myeloid Leukemia Patients Receiving Dasatinib or Nilotinib: A Real-World Retrospective Healthcare Claims Study in the United States.
    Seiter K; Latremouille-Viau D; Guerin A; Ndife B; Habucky K; Tang DH; Pivneva I; Gagnon-Sanschagrin P; Joseph GJ
    Adv Ther; 2018 Oct; 35(10):1671-1685. PubMed ID: 30155792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient Support Program Increased Medication Adherence with Lower Total Health Care Costs Despite Increased Drug Spending.
    Brixner D; Rubin DT; Mease P; Mittal M; Liu H; Davis M; Ganguli A; Fendrick AM
    J Manag Care Spec Pharm; 2019 Jul; 25(7):770-779. PubMed ID: 31081461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic and Clinical Burden of Acute Myeloid Leukemia Episodes of Care in the United States: A Retrospective Analysis of a Commercial Payer Database.
    Pandya BJ; Chen CC; Medeiros BC; McGuiness CB; Wilson SD; Walsh EH; Wade RL
    J Manag Care Spec Pharm; 2020 Jul; 26(7):849-859. PubMed ID: 32281456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of a Patient Support Program on Patient Adherence to Adalimumab and Direct Medical Costs in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis.
    Rubin DT; Mittal M; Davis M; Johnson S; Chao J; Skup M
    J Manag Care Spec Pharm; 2017 Aug; 23(8):859-867. PubMed ID: 28737994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increasing economic burden of tyrosine kinase inhibitor treatment failure by line of therapy in chronic myeloid leukemia.
    McGarry LJ; Chen YJ; Divino V; Pokras S; Taylor CR; Munakata J; Nieset CC; Huang H; Jabbour E; Malone DC
    Curr Med Res Opin; 2016; 32(2):289-99. PubMed ID: 26566171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The costs of treating and not treating patients with chronic myeloid leukemia with tyrosine kinase inhibitors among Medicare patients in the United States.
    Seymour EK; Ruterbusch JJ; Winn AN; George JA; Beebe-Dimmer JL; Schiffer CA
    Cancer; 2021 Jan; 127(1):93-102. PubMed ID: 33119175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health care resource utilization and costs associated with nonadherence and nonpersistence to antidepressants in major depressive disorder.
    Ta JT; Sullivan SD; Tung A; Oliveri D; Gillard P; Devine B
    J Manag Care Spec Pharm; 2021 Feb; 27(2):223-239. PubMed ID: 33506730
    [No Abstract]   [Full Text] [Related]  

  • 18. The Economic Burden of End-Organ Damage Among Medicaid Patients with Sickle Cell Disease in the United States: A Population-Based Longitudinal Claims Study.
    Campbell A; Cong Z; Agodoa I; Song X; Martinez DJ; Black D; Lew CR; Varker H; Chan C; Lanzkron S
    J Manag Care Spec Pharm; 2020 Sep; 26(9):1121-1129. PubMed ID: 32597290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medication adherence, molecular monitoring, and clinical outcomes in patients with chronic myelogenous leukemia in a large HMO.
    Haque R; Shi J; Chung J; Xu X; Avila C; Campbell C; Ahmed SA; Chen L; Schottinger JE
    J Am Pharm Assoc (2003); 2017; 57(3):303-310.e2. PubMed ID: 28259737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment patterns, overall survival, healthcare resource use and costs in elderly Medicare beneficiaries with chronic myeloid leukemia using second-generation tyrosine kinase inhibitors as second-line therapy.
    Smith BD; Liu J; Latremouille-Viau D; Guerin A; Fernandez D; Chen L
    Curr Med Res Opin; 2016 May; 32(5):817-27. PubMed ID: 26743563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.